1788873-48-2 Usage
Description
(2,2-difluorohexahydro-1H-pyrrolizin-7a-yl)methanol is a synthetic compound featuring a fluorine-substituted pyrrolizine ring. This molecule is utilized in pharmaceutical research and development, with the incorporation of fluorine atoms aimed at enhancing its pharmacological properties. The addition of fluorine is known to improve the compound's metabolic stability, bioavailability, and target selectivity, making it a promising candidate for the development of new drugs across various therapeutic areas.
Uses
Used in Pharmaceutical Research and Development:
(2,2-difluorohexahydro-1H-pyrrolizin-7a-yl)methanol is used as a research compound for the development of new drugs due to its unique structural features and potential pharmacological benefits. The presence of fluorine atoms is expected to contribute to the compound's improved metabolic stability, bioavailability, and target selectivity, which are crucial for drug efficacy and safety.
Used in Antiviral Drug Development:
In the antiviral industry, (2,2-difluorohexahydro-1H-pyrrolizin-7a-yl)methanol is used as a potential drug candidate for the development of antiviral treatments. Its unique structure and fluorine substitution may offer advantages in targeting viral processes and improving the effectiveness of antiviral therapies.
Used in Antibacterial Drug Development:
Within the antibacterial sector, (2,2-difluorohexahydro-1H-pyrrolizin-7a-yl)methanol is employed as a candidate for the creation of new antibacterial agents. (2,2-difluorohexahydro-1H-pyrrolizin-7a-yl)methanol's properties may contribute to overcoming bacterial resistance and providing more effective treatment options for various infections.
Used in Anti-inflammatory Drug Development:
In the field of anti-inflammatory drug development, (2,2-difluorohexahydro-1H-pyrrolizin-7a-yl)methanol is utilized as a potential therapeutic agent. Its structural and pharmacological attributes may aid in the management of inflammation and the treatment of related conditions, offering new avenues for therapeutic intervention.
Check Digit Verification of cas no
The CAS Registry Mumber 1788873-48-2 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,7,8,8,8,7 and 3 respectively; the second part has 2 digits, 4 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 1788873-48:
(9*1)+(8*7)+(7*8)+(6*8)+(5*8)+(4*7)+(3*3)+(2*4)+(1*8)=262
262 % 10 = 2
So 1788873-48-2 is a valid CAS Registry Number.
1788873-48-2Relevant articles and documents
Discovery of selective, orally bioavailable, N-linked arylsulfonamide Nav1.7 inhibitors with pain efficacy in mice
Roecker, Anthony J.,Egbertson, Melissa,Jones, Kristen L.G.,Gomez, Robert,Kraus, Richard L.,Li, Yuxing,Koser, Amy Jo,Urban, Mark O.,Klein, Rebecca,Clements, Michelle,Panigel, Jacqueline,Daley, Christopher,Wang, Jixin,Finger, Eleftheria N.,Majercak, John,Santarelli, Vincent,Gregan, Irene,Cato, Matthew,Filzen, Tracey,Jovanovska, Aneta,Wang, Ying-Hong,Wang, Deping,Joyce, Leo A.,Sherer, Edward C.,Peng, Xuanjia,Wang, Xiu,Sun, Haiyan,Coleman, Paul J.,Houghton, Andrea K.,Layton, Mark E.
, p. 2087 - 2093 (2017)
The voltage-gated sodium channel Nav1.7 is a genetically validated target for the treatment of pain with gain-of-function mutations in man eliciting a variety of painful disorders and loss-of-function mutations affording insensitivity to pain.
BICYCLOAMINE-SUBSTITUTED-N-BENZENESULFONAMIDE COMPOUNDS WITH SELECTIVE ACTIVITY IN VOLTAGE-GATED SODIUM CHANNELS
-
Paragraph 0189, (2015/06/11)
Disclosed are compounds of Formula (A-a), or a salt thereof, Where "B1" and "R1" through "R5" are as defined herein, which compounds have properties for blocking Nav 1.7 ion channels found in peripheral and sympathetic neurons. Also described are pharmaceutical formulations comprising the compounds of Formula (A-a) or their salts, and methods of treating neuropathic pain disorders using the same.
